A new partnership for BiomeBank with the clinical-stage microbiome therapeutics company announcing an agreement with Hudson Institute of Medical Research.
The organisations have signed a Memorandum of Understanding that will enable BiomeBank to bring its experience in the discovery and development of microbial therapies to enable the translation of Hudson Institute’s microbiome research.
The partnership will initially focus on the development of defined and targeted microbial therapies to treat unmet medical need for patients with Inflammatory Bowel Disease (IBD).
BiomeBank, which has recently launched its Series-A funding round, has signed a four-year collaborative agreement with Hudson Institute. BiomeBank will gain access to important research on how the microbiota could treat paediatric IBD.
BiomeBank CEO Thomas Mitchell said, “The combined strengths of the two organisations will put the new partnership at the forefront of the discovery and development of defined and targeted microbial therapies.
“Together with Hudson Institute and along with its plans to establish a world-class NCIR, we’ll work to identify the key microbial strains which play a role in IBD and combine our capabilities to develop a safe and effective microbial therapy for patients.
“This partnership places Australia firmly on the map as a world-leader in the development of a new class of therapies to treat unmet medical need across the globe.”
Hudson Institute Director and CEO, Professor Elizabeth Hartland, said, “The partnership between Hudson Institute and BiomeBank is a critical first step in translating our microbiome discoveries and developing a new generation of treatments for patients.”
Leading microbiome researcher from Hudson Institute, Dr Samuel Forster, added, “The partnership will place Australia at the forefront of microbial research and drug discovery.
“Through our work at Hudson Institute, we have developed new ways to isolate human bacteria, resulting in one of the most diverse collections of human commensal bacteria in the world and a detailed understanding of how these may protect against disease.
“Modifying the microbiome as a treatment represents a new way of doing medicine. Working with BiomeBank will provide the opportunity to apply our cutting-edge discoveries to improve patients’ lives.”